Business
AtriCure sells surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operating pain management.
AtriCure revenue rose 14.9%, losses narrowed, and free cash flow improved sharply, with grey Altman-Z but safe EQ.
The read at a glance✓ Audited against SEC data
- Business mix — Afib, LAA, and pain therapiesNote
- Revenue — Revenue rose 14.9%OK
- Losses — Net loss narrowed to $11.4MOK
- Cash — FCF rose to $48.3MOK
- Margins — Gross and FCF margins improvedOK
- Insiders — 0 buys / 10 sellsWatch
- Accounting — Altman-Z grey; EQ safeNote
Where the revenue comes from
Fiscal 2025, as AtriCure, Inc. reports it. History and quarterly detail are in the app.
- Appendage management$220.2M
- Open ablation$184.9M
- Pain management$89.6M
- Minimally invasive ablation$39.8M
- Shipping and Handling$2.5M
Leadership changes
From AtriCure, Inc.'s own filings, the day they're filed.
- Biosense Webster · director · appointment
Latest filings
- 10-Q · Quarterly report2026-07-27
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AtriCure, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.